Experimental combo targets Hard-to-Treat lung cancer
NCT ID NCT02812667
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—nivolumab, a standard immunotherapy, and plinabulin, an experimental drug that attacks tumor blood vessels—in 18 people with advanced non-small cell lung cancer that had worsened after chemotherapy. The main goals were to find a safe dose and check for side effects. Researchers also tracked whether tumors shrank or stopped growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and plinabulin
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced lung cancer patients who have run out of standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety and dosing, not effectiveness. The drug combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lung cancer drug designed for one mutation work for another?
- Could chemo plus immunotherapy double the punch against tough lung cancers?
- Should all advanced lung cancer patients get a brain scan? new trial aims to find out
- New hope for tough lung cancer? trial tests targeted drug against chemo
- New combo therapy for lung cancer under Real-World watch
- New combo tackles lung cancer after immunotherapy fails